Hsbc Holdings PLC Decreases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Hsbc Holdings PLC decreased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,588 shares of the specialty pharmaceutical company’s stock after selling 726 shares during the period. Hsbc Holdings PLC owned 0.06% of Collegium Pharmaceutical worth $663,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in COLL. Gladius Capital Management LP bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at approximately $32,000. nVerses Capital LLC boosted its stake in Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the period. Sheaff Brock Investment Advisors LLC bought a new position in Collegium Pharmaceutical during the first quarter valued at $204,000. Gallacher Capital Management LLC bought a new position in Collegium Pharmaceutical during the first quarter valued at $223,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Collegium Pharmaceutical by 62.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,120 shares of the specialty pharmaceutical company’s stock valued at $238,000 after acquiring an additional 2,344 shares during the period.

Insider Buying and Selling

In other news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on COLL shares. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Truist Financial raised their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the company from $41.00 to $44.00 in a report on Friday, June 7th. HC Wainwright increased their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Finally, Piper Sandler reissued a “neutral” rating and set a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Trading Down 0.5 %

Shares of NASDAQ COLL opened at $38.26 on Monday. Collegium Pharmaceutical, Inc. has a twelve month low of $20.95 and a twelve month high of $40.95. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The business has a fifty day simple moving average of $36.69 and a two-hundred day simple moving average of $35.49. The firm has a market cap of $1.25 billion, a PE ratio of 15.94 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. During the same period in the prior year, the firm earned $1.13 earnings per share. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. Analysts expect that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.